SANA · Nasdaq · CIK 0001770121
Sana Biotechnology, Inc.
Sana Biotechnology, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 6, 2026. Its EDGAR record lists 22 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- Sana Biotechnology, Inc.
- Ticker
- SANA
- SEC Central Index Key (CIK)
- 0001770121
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (code 2836)
- Business address
- SEATTLE, WA
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- <br>Emerging growth company
- Position in SEC ticker list
- #2663 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from Sana Biotechnology, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$355.9M | -$269.5M | -$283.3M | -$266.8M | -$244.2M |
| Diluted EPS | -$2.14 | -$1.43 | -$1.46 | -$1.16 | -$0.96 |
| Total assets | $1.1B | $822.7M | $565.3M | $501.0M | $416.9M |
| Cash and equivalents | $253.0M | $176.8M | $133.5M | $127.6M | $71.9M |
XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Mar 3, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 10, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Sep 8, 2026 | 8-K | Regulation FD disclosure· period Sep 8, 2026 | Document · Index |
| Apr 24, 2026 | DEF 14A | Definitive proxy statement· period Jun 4, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about Sana Biotechnology, Inc., by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 6, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 5, 2026 | Document · Index |
| Sep 8, 2026 | 8-K | Regulation FD disclosure· period Sep 8, 2026 | Document · Index |
| Aug 27, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 26, 2026 | Document · Index |
| Aug 14, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Aug 10, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 10, 2026 | 8-K | Results of operations· period Aug 10, 2026 | Document · Index |
| Jul 7, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 6, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 5, 2026 | 8-K | Shareholder vote results· period Jun 4, 2026 | Document · Index |
| May 21, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| May 15, 2026 | 8-K | Other events· period May 15, 2026 | Document · Index |
| May 11, 2026 | S-8 | Registration of employee benefit plan securities | Document · Index |
| May 11, 2026 | 10-Q | Quarterly report· period Mar 31, 2026 | Document · Index |
| May 11, 2026 | 8-K | Results of operations· period May 11, 2026 | Document · Index |
| Apr 24, 2026 | ARS | ARS· period Dec 31, 2025 | Document · Index |
| Apr 24, 2026 | DEFA14A | Additional proxy soliciting materials | Document · Index |
| Apr 24, 2026 | DEF 14A | Definitive proxy statement· period Jun 4, 2026 | Document · Index |
| Apr 24, 2026 | 8-K | Director or officer change· period Apr 22, 2026 | Document · Index |
| Apr 13, 2026 | 424B5 | 424B5 | Document · Index |
| Apr 13, 2026 | 8-K | Other events· period Apr 10, 2026 | Document · Index |
| Apr 8, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 6, 2026 | Document · Index |
| Mar 27, 2026 | 3 | Initial statement of beneficial ownership· period Mar 24, 2026 | Document · Index |
| Mar 10, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 6, 2026 | Document · Index |
| Mar 10, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 6, 2026 | Document · Index |
| Mar 6, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 5, 2026 | Document · Index |
| Mar 6, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 5, 2026 | Document · Index |
| Mar 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 2, 2026 | Document · Index |
| Mar 3, 2026 | S-3ASR | Simplified registration statement | Document · Index |
| Mar 3, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Mar 3, 2026 | 8-K | Results of operations; Other events· period Mar 3, 2026 | Document · Index |
| Feb 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Feb 17, 2026 | Document · Index |
| Feb 18, 2026 | 3 | Initial statement of beneficial ownership· period Feb 17, 2026 | Document · Index |
| Feb 17, 2026 | 8-K | Director or officer change; Regulation FD disclosure· period Feb 17, 2026 | Document · Index |
Insider filing activity
22 Form 4 filings appear in Sana Biotechnology, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Biological Products, (No Diagnostic Substances)
- AMGN AMGEN INC
- GILD GILEAD SCIENCES, INC.
- MRNA Moderna, Inc.
- ARGX ARGENX SE
- RVMD Revolution Medicines, Inc.
- BIIB BIOGEN INC.
- BNTX BioNTech SE
- EXEL EXELIXIS, INC.
All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in Washington
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001770121 and XBRL company facts. Sana Biotechnology, Inc. on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement